Goodwin advised Flagship Pioneering as lead investor in an approximately $25.5 million private placement of Evelo Biosciences, Inc.’s common stock. Evelo’s common stock is listed on the Nasdaq Global Select Market under the symbol “EVLO.”
Evelo is a clinical-stage biotechnology company focused on treating all stages of inflammatory diseases such as psoriasis, atopic dermatitis, asthma, food allergies, arthritis, inflammatory bowel disease and neuroinflammatory diseases. Evelo's work aims to harness the small intestinal axis to modulate the body's immune system.
Flagship creates, resources and builds life sciences companies that invent breakthrough technologies in order to transform health care and sustainability. Over nearly two decades, this approach has enabled Flagship to originate and foster the development of around 100 science-based companies, resulting in more than $30 billion in aggregate value, thousands of patents and a pipeline of more than 50 clinical development programs.
The deal team consisted of Stuart Cable, James Matarese, Bryan Quinn and Griffin Drake and Dan Karelitz and Matthew Dunay, with invaluable assistance from Jocelyn Arel, Arman Oruc, and Adam Slutsky.
For additional details on the transaction, please read the press release.